Varicella-zoster virus (VZV) infection has been treated mainly with acyclovir (ACV) and penciclovir, both of which are anti-viral nucleoside analogues that exhibit anti-VZV activity through phosphorylation by thymidine kinase (TK) and inhibition of viral DNA synthesis (Elion et al
The nucleotide changes of the DNA polymerase gene and the susceptibility of acyclovir (ACV)-resistant varicella-zoster virus (VZV) mutants to anti-herpetic drugs were determined and compared to those of herpes simplex virus type 1 (HSV-1) mutants. The seven ACV-resistant VZV mutants were classified into three groups, N 779 S, G 805 C and V 855 M, according to the sequences of their DNA polymerase genes. The amino acid substitutions N 779 S and G 805 C were identical in position to the N 815 S and G 814 C mutations in the HSV-1 DNA polymerase mutants, respectively, and the V 855 M amino acid substitution was similar to the HSV-1 V 892 M mutation. All three groups of VZV mutants were susceptible to ACV, phosphonoacetic acid, vidarabine and aphidicolin, at levels similar to those seen with the respective HSV-1 mutants, except for subtle differences that were due possibly to the non-conserved regions in their sequences. Although both the HSV-1 and the VZV DNA polymerase genes show 53 % sequence similarity, both viruses essentially show a similar biochemical behaviour.
Varicella-zoster virus (VZV) infection has been treated mainly with acyclovir (ACV) and penciclovir, both of which are anti-viral nucleoside analogues that exhibit anti-VZV activity through phosphorylation by thymidine kinase (TK) and inhibition of viral DNA synthesis (Elion et al., 1977 ; Biron & Elion, 1980 ; Elion, 1993 ; Boyd et al., 1987) . In immunocompetent hosts and in clinical practice, conventional ACV Author for correspondence : Kimiyasu Shiraki.
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The DDBJ accession nos for the VZV reported in this study are as follows : VZV parent Kawaguchi strain (AB059828) ; ACV-resistant VZV mutants A6 and A8 (AB059829) ; A1, A3 and A4 (AB059830) ; and A2 and A5 (AB059831).
treatments rarely generate ACV-resistant viruses. However, in immunocompromised hosts, such as patients in the late phase of human immunodeficiency virus infection, VZV infection tends to be severe and prolonged ; ACV-resistant VZV mutants have emerged after long-term treatment with ACV (Pahwa et al., 1988 ; Hoppenjans et al., 1990 ; Jacobson et al., 1990 ; Talarico et al., 1993 ; Boivin et al., 1994 ; Snoeck et al., 1994) . Most of the ACV-resistant mutants that have been isolated either from cell culture or from patients have mutations within the TK gene. However, the DNA polymerase of foscarnetresistant VZV isolated from a patient with AIDS has been characterized and the mutation responsible for the foscarnet resistance was located within the non-conserved region of the DNA polymerase gene (Visse et al., 1998) .
In this study, we determined the nucleotide changes in the DNA polymerase gene of ACV-resistant VZV mutants. These mutants were analysed for their susceptibility to anti-herpetic drugs. In addition, we have demonstrated identical amino acid substitutions and a discrete discrepancy in the drug susceptibility between VZV and herpes simplex virus type 1 (HSV-1) DNA polymerase mutants.
Human embryonic lung (HEL) cells were grown and maintained in Eagle's minimum essential medium supplemented with 10 % foetal bovine serum (FBS) for growth or 2 % FBS for maintenance. We used the VZV parent Kawaguchi strain which was serially plaque-purified six times using cellfree virus (Shiraki et al., 1983 (Shiraki et al., , 1985 (Shiraki et al., , 1992 . The ACV-resistant virus strains A1-A6 and A8, each with mutations in the DNA polymerase gene, were isolated in the presence of increasing concentrations (4n5, 11n3 and 22n5 µg\ml) of ACV (100 µM). Mutants were passaged three times at each concentration until the appearance of typical cytopathology. After two plaque purification steps in the presence of 100 µM ACV, the plaquepurified viruses were used as ACV-resistant mutants (Shiraki et al., 1983 (Shiraki et al., , 1990 .
VZV DNA was prepared from cell cultures infected with the parent Kawaguchi strain or from the various mutants (Shiraki et al., 1991 a, b) . The 3n6 kb fragment encoding the VZV DNA polymerase gene was amplified by PCR and sequenced using the Auto Sequencer Core kit (Toyobo) with Cy5-labelled primers designed according to the sequence of VZV Dumas strain (Davison & Scott, 1986 Larder et al. (1987) ; 2, Gibbs et al. (1988) ; 3, Tsurumi et al. (1987) ; 4, Knopf & Weisshart (1988) ; 5, Hwang et al. (1992) ; 6, Marcy et al. (1990) ; 7, Collins et al. (1989) ; 8, Chiou et al. (1995) ; 9, Visse et al. (1998) ; 10, Collins & Darby (1991) ; 11, Visse et al. (1999 Analysis of VZV DNA polymerase mutants Analysis of VZV DNA polymerase mutants sequencing reaction products were run on the ALF DNA Sequencer (Pharmacia).
The susceptibility of each ACV-resistant VZV mutant to ACV (Sigma), phosphonoacetic acid (PAA) (Sigma), 9-β--arabinofuranosyladenine (Ara-A) (ICN) and aphidicolin (Aph) (Wako Pure Chemical Industries) was determined by plaque reduction assays in HEL cells (Ida et al., 1999 ; Shiraki et al., 1983 Shiraki et al., , 1992 . Briefly, confluent monolayers of HEL cells in 60 mm plastic Petri dishes (in duplicate) were inoculated with 100 p.f.u. per dish of cell-free virus in 0n2 ml SPGC medium (PBS supplemented with 5 % sucrose, 0n1 % sodium glutamate and 10 % FBS). After incubation for 1 h to permit adsorption, 5 ml of maintenance medium and the various concentrations of drug were added. After 5 days of incubation, cells were fixed and stained, after which plaques were counted. The 50 % effective concentration (EC &! ) was defined as the concentration that reduced plaque formation by 50 %.
Genotypic and phenotypic characterizations of ACVresistant mutants are summarized in Table 1 . Sequence analysis of the DNA polymerase gene of ACV-resistant mutants showed that each mutant had a single nucleotide substitution. All seven ACV-resistant mutants showed only a single amino acid change in the whole protein. The ACV-resistant mutants A1, A3 and A4 showed a G T change at nucleotide position 48224, which resulted in the amino acid substitution G)!&C. These three mutants were resistant to ACV and PAA, sensitive to Ara-A and hypersensitive to Aph. The ACV-resistant mutants A2 and A5 showed a G A change at nucleotide position 48074, which resulted in the amino acid substitution V)&&M. These two mutants were resistant to ACV, PAA and Ara-A and hypersensitive to Aph. The ACV-resistant mutants A6 and A8 showed an A G change at nucleotide position 48301, which resulted in the amino acid substitution N((*S. These two mutants were resistant to ACV, sensitive to Aph and hypersensitive to PAA and Ara-A. Thus, seven ACVresistant mutants were classified into three groups according to their genotypic and phenotypic characterizations. Mutations in the TK gene of ACV-resistant mutants were observed near the guanosine homopolymer in HSV (Sasadeusz et al., 1997) or downstream from two sequential guanosine nucleotides in VZV (Ida et al., 1999) , but the nucleotide changes in the VZV DNA polymerase gene were not related to these sequences, thus indicating that these mutations were probably not induced by ACV.
The vast majority of drug-resistant mutations in the HSV-1 DNA polymerase gene reported previously have been mapped within the conserved regions I-III and A (Larder et al., 1987 ; Marcy et al., 1990 ; Chiou et al., 1995 ; Andrei et al., 2000) . Many drug-resistant mutations were reported to be located especially within regions II and III. We compared the DNA polymerase gene sequence of the parent Kawaguchi strain used in this study with that of the Dumas strain in the EMBL database. The parent Kawaguchi strain had six nucleotide differences compared with the Dumas strain ; T C at nucleotide position 47162, G A at nucleotide position 47939, A G at nucleotide position 48050, C T at nucleotide positions 48825 and 49535 and G T at nucleotide position 50081, resulting in three amino acid substitutions, G")'C, S)'$G and C""&*R (Fig. 1) . The amino acid changes between the Kawaguchi and the Dumas strains were located in non-conserved regions within the DNA polymerase gene. These data suggest that the difference in DNA sequence between the two strains may not effect the enzyme activity of the DNA polymerase. Visse et al. (1998) have reported a foscarnet-resistant VZV strain from a patient with AIDS ; its amino acid changes compared with the Dumas strain are E&"#K and S)'$G (Fig. 1) . The amino acid substitution at residue 863 is identical to that in the Kawaguchi strain. Visse et al. (1998) reported that the E&"#K substitution in the non-conserved region implicated foscarnet resistance. Collins & Darby (1991) have reported two ACV-resistant VZV mutants with A')%T and N((*S mutations in the VZV DNA polymerase gene. The latter mutation is identical to the N((*S mutation in our study.
We compared the mutations of the VZV DNA polymerase gene with those of the HSV-1 DNA polymerase gene, as shown in Fig. 1 . The positions of the three mutations at amino acid residues 779, 805 and 855 found in the ACV-resistant VZV corresponded to amino acid residues 815, 841 and 890 of HSV-1, respectively, which were within the conserved regions III and I of the HSV-1 DNA polymerase gene. The mutations found at residues 779 and 805 of VZV were identical to residues 815 and 841 in HSV-1, respectively, as reported previously (Larder et al., 1987 ; Chiou et al., 1995) . Region III of the VZV DNA polymerase gene may interact directly with drug-substrate binding, in a manner similar to that of the conserved region III of the HSV-1 DNA polymerase gene (Larder et al., 1987 ; Gibbs et al., 1988) . Marcy et al. (1990) have reported that one of the HSV-1 DNA polymerase mutations has a V)*#M change. Although V)&& of VZV corresponds to I)*! of HSV-1, as shown in Fig. 1 , the V)&&M mutation in VZV may correspond to the V)*#M mutation in HSV-1 by way of biochemical behaviour.
We compared the drug susceptibility of the VZV DNA polymerase mutants with those reported for the HSV-1 DNA polymerase mutants (Table 2) containing identical amino acid substitutions (Larder et al., 1987 ; Chiou et al., 1995 ; Marcy et al., 1990) . This indicates that the role of the conserved regions is identical between the two DNA polymerases. The HSV-1 mutants with the N)"&S mutation were susceptible to PAA and Ara-A and more resistant to ACV, similar to the VZV mutants with the N((*S mutation. Although HSV-1 N)"&S mutants were resistant to Aph, VZV N((*S mutants were as sensitive to Aph as wild-type VZV. The mutants with a G to C change at amino acids 841 and 805 of HSV-1 and VZV, respectively, showed similar susceptibility to Ara-A and were resistance to both ACV and PAA. The mutants with a V to M change at 892 of HSV-1 and 855 of VZV showed similar susceptibility to Table 2 . Comparison of the sensitivity of ACV-resistant HSV-1 to anti-herpetic drugs with ACV-resistant VZV The ratio of sensitivity was determined as the EC &! ratio of the mutant over the parent. The substitutions N)"&S, G)%"C and V)*#M of the HSV-1 mutants were referenced from Larder et al. (1987) , Coen et al. (1985) and Marcy et al. (1990) , respectively.
Ratio of sensitivity Amino acid Virus substitution Clone ACV PAA Ara-A Aph
* These data were obtained from Marcy et al. (1990) . , No data.
Aph and similar resistance to PAA. Among the four antiherpetic drugs, the VZV V)&&M mutant was more resistant to ACV than the HSV-1 V)*#M mutant. In spite of both the identical and similar amino acid substitutions, ACV-resistant mutants of VZV and HSV-1 showed a different susceptibility to ACV and Aph. It was suggested that the discrepancy in drug susceptibility between HSV-1 and VZV might be reflected from the non-conserved regions, which may have caused a minute difference in the affinity of the DNA polymerase to ACV and Aph. In this study, the seven ACV-resistant VZV mutants were classified into three groups, N((*S, G)!&C and V)&&M, according to the sequences of their DNA polymerase genes. The amino acid substitutions N((*S and G)!&C were identical in position to N)"&S and G)"%C, respectively, and V)&&M was similar in position to V)*#M, as reported for the HSV-1 DNA polymerase mutants (Fig. 1) . The sequence similarity between the HSV-1 and the VZV DNA polymerase genes is only 53 %, but both DNA polymerases are biochemically similar, due possibly to the highly conserved regions that are essential for enzyme activity. The N((*S and V)&&M mutants exhibited a discrepancy in the ratio of sensitivity to ACV or Aph in comparison to the corresponding HSV-1 mutants. It was suggested that the different conformations created by the differences in the non-conserved regions of VZV and HSV-1 may have caused the discrepancy in drug susceptibility of the ACV-resistant mutants with identical and similar amino acid substitutions.
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